Clinical application of intraperitoneal chemotherapy before surgery for ovarian cancer and its evaluation

  • Dianyun Shi
  • Mei Xiao
  • Saiying Chen
  • Bin Yang
  • Qijiang Zhu
  • Pingping Xu
  • Chenfang Su
Article

Abstract

Objective

To investigate the clinical efficacy of intraperitoneal chemotherapy before surgery for ovarian cancer.

Methods

60 patients with stages II–IV of ovarian cancer were treated with intraperitoneal chemotherapy of CAP or TP regimen followed by a surgery treatment and another chemotherapy for 6 cycles. And then the efficiency of the therapy was evaluated by analyzing the changes of ascites, the serum CA-125 and CA-19-9 levels and the findings in the operation, and investigating the recurrence of cancer and the survival.

Results

After 1–3 cycles of intraperitoneal chemotherapy, serum levels of CA-125 and CA-19-9 and carcinous ascites significantly reduced in all patients, ascites reduce was over 50% in 98.3% cases; all cases were successfully treated with cytoreduction and it was found during the operation that bulky tumor was reduced and looser so as to be easily isolated and removed; PFS of the patients was prolonged, while the toxicity and side-effects were not so serious as beyond the patient toleration.

Conclusion

Intraperitoneal chemotherapy before surgery for ovarian cancer has an active efficacy in clinic, being able to improve conditions of surgery and increase the opportunity of maximal cytoreduction, and prolong survival of the patients, and should be a good selection for the treatment of advanced ovarian cancer.

Key words

ovarian cancer intraperitoneal chemotherapy clinical application evaluation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56: 106–130.PubMedCrossRefGoogle Scholar
  2. 2.
    Gadducci A, Cosio S, Conte PF, et al. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol, 2005, 55: 153–166.PubMedCrossRefGoogle Scholar
  3. 3.
    Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol, 2006, 17: v181–187.PubMedCrossRefGoogle Scholar
  4. 4.
    Bristow RE, Tomacruz RS, Armstong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002, 20: 1248–1259.PubMedCrossRefGoogle Scholar
  5. 5.
    Feng YJ, Shen K. Obstetrics & gynecology (Chinese). Beijing: People’s Medical Publishing House, 2005. 330–345.Google Scholar
  6. 6.
    Zhou JH. Practical oncology medicine (Chinese). 2nd edition. Beijing: People’s Medical Publishing House, 2003. 47.Google Scholar
  7. 7.
    Yang DM, Gao XD, Meng XY, et al. Value of ultrasound for measurement of ascites fluid volume. J Clin Inter Med (Chinese), 1999, 16: 255–256.Google Scholar
  8. 8.
    Jaaback K, Johson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev, 2006, (1): CD005340.Google Scholar
  9. 9.
    Hamilton CA, Berek JS. Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol, 2006, 18: 507–515.PubMedCrossRefGoogle Scholar
  10. 10.
    Alhayki M, Hopkins L, Le T. Intraperitoneal chemotherapy for epithelial ovarian cancer. Obstet Gynecol Surv, 2006, 61: 529–534.PubMedCrossRefGoogle Scholar
  11. 11.
    Ba CX, Wang YL, Han AL, et al. Combined intraperitoneal carboplatin infusion with systemic docetaxel chemotherapy in treatment of advanced ovarian cancers. Chin Clin Oncol (Chinese), 2007, 12: 140–141.Google Scholar
  12. 12.
    Zhang D, Wang SL. Intraperitoneal chemotherapy before surgery in stage IIIc epithelial ovarian carcinoma with ascites. J Pract Obstet Gynecol (Chinese), 2000, 16: 304–305.Google Scholar
  13. 13.
    Markman M, Bundy BN, Alberts DS, et al. Phase III trail of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol, 2001, 19: 1001–1007.PubMedGoogle Scholar
  14. 14.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 2006, 354: 34–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Elit L, Oliver TK, Covens A, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer, 2007, 109: 692–702.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Dianyun Shi
    • 1
  • Mei Xiao
    • 1
  • Saiying Chen
    • 1
  • Bin Yang
    • 1
  • Qijiang Zhu
    • 1
  • Pingping Xu
    • 1
  • Chenfang Su
    • 1
  1. 1.Department of Obstetrics and Gynecology81 Hospital of PLANanjingChina

Personalised recommendations